Modification of Nitrosamine Carcinogenesis by Ascorbic Acid

  • P. Bogovski
  • R. Birk
  • L. Kildema
  • L. Teras


The modifying action of ascorbic acid (AA) on endogenous formation of NNitroso compounds is well known. We have studied the action of AA on the mortality of rats due to hepatoma induced by N-nitrosodiethylamine (NDEA) and on the activity of some marker enzymes of hepatocarcinogenesis. AA (50 mg per animal intraperitoneally three times a week during three months) accelerated the NDEA induced hepatocarcinogenesis. In the NDEA group one rat died after 400 days, in the NDEA+AA group 11 rats (P<0.01). At later stages the mortality difference of both groups was less distinct. The macroscopic grading of hepatomas in necropsied rats of the NDEA+AA group was significantly higher (grade 4.41) than in the NDEA only group (grade 3.09, P<0.02). Administration of AA augmented the increase of activity of glucose-6-phosphate dehydrogenase and the decrease of the activity of glucose-6-phosphatase compared with activities in the NDEA group. The activity of hexokinase, pyruvate kinase and glucose-6-phosphate dehydrogenase in the liver increased in the NDEA+AA group much earlier than in the NDEA group. The accelerating action of high doses of AA on nitrosamine hepatocarcinogenesis has to be taken into account in cancer chemoprevention and treatment.


Ascorbic Acid Pyruvate Kinase Betel Quid Endogenous Formation Lung Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Doll, R. and Peto, R. (1981) J. Natl. Cancer Inst. 66, 1191–1308PubMedGoogle Scholar
  2. 2.
    Mirvish, S.S. (1986) Cancer 58, 1842–1850PubMedCrossRefGoogle Scholar
  3. 3.
    Nair, J., Nair, U.J., Ohshima, H., Bhide, S.V., Bartsch, H. (1987) in Relevance of N-nitroso compounds to human cancer: Exposures and mechanism. IARC Sci. Publ., 84, p. 465–469PubMedGoogle Scholar
  4. 4.
    Fukushima, S., Imaida, R., Sakata, T., Okamura, T., Shibata, M. and Ito, N. (1983) Cancer Res., 43, 4454–4457PubMedGoogle Scholar
  5. 5.
    Cameron, E., Pauling, L., Leibovitz, B. (1979) Cancer Res. 39, 663–681PubMedGoogle Scholar
  6. 6.
    Moertel, C.C., Fleming, T.R., Creagan, E.T., Rubin, J., O’Connel, M.J. and Ames M.M. (1985) N. Engl. J. Med. 312, 137–141PubMedCrossRefGoogle Scholar
  7. 7.
    Ton, C.C.T., Fong, L.Y.Y. (1984) Carcinogenesis 5, 533–536PubMedCrossRefGoogle Scholar
  8. 8.
    Mirvish, S.S. (1981) in Inhibition of tumor induction and development. (eds M.S. Zedeck and M. Lipkin) Plenum Press, NY a. London, pp. 101–126Google Scholar
  9. 9.
    Peto, R., Pike M.C., Day, N.E., Gray, R.G., Lee, P.N., Parish, S., Peto, J., Richards, S., Wahrendorf, J. in Long-term and short-term screening assays for carcinogens: a critical appraisal. IARC Monographs, suppl. 2.–Lyon, 1980 pp. 311–426Google Scholar
  10. 10.
    Gurkalo. V.K., Zabezhinski, M.A. (1982) Neoplasma 29, 301–307PubMedGoogle Scholar
  11. 11.
    Zannoni, V.G., Holsztynska, E.G., Lau, S.S. (1982) in Ascorbic Acid: Chemistry, Metabolism and Uses. 2nd Chem. Congr. N. Amer. Contin. Washington, D.C., pp. 349–368CrossRefGoogle Scholar
  12. 12.
    Omaye, S.T., Turnbull, J.D. (1980) Life Sci. 27, 441–449PubMedCrossRefGoogle Scholar
  13. 13.
    Rikans, L.E. (1982) J. Pharmacol. Exp. Ther. 204, 702–713Google Scholar
  14. 14.
    Horio, F., Ozaki, K., Kohmura, M., Yoshida, A., Makino S. and Hayashi, Y. (1986) J. Nutr., 116, 2278–2289PubMedGoogle Scholar
  15. 15.
    Rubenchik, B.L., Juchimenko, M.D., Boim, T.M., Mihhailenko, V.M. (1988) Eksperimentalnaya Onkologiya (Russ.) 10, 29–32Google Scholar
  16. 16.
    Diaz-Gomez, M.I., Swann, P.F., Magee, P.N. (1977) Biochem. J., 164, 497–500Google Scholar
  17. 17.
    Keeman T.H., Weinkaro, R.T. (1985) Toxicol. and Appl. Pharmacol. 78, 316–320CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • P. Bogovski
    • 1
  • R. Birk
    • 1
  • L. Kildema
    • 1
  • L. Teras
    • 1
  1. 1.Institute of Experimental and Clinical MedicineTallinnUSSR

Personalised recommendations